"At current levels (even adjusting for option dilution), CHM is...

"At current levels (even adjusting for option dilution), CHM is ridiculously cheap!"

Compared to any other listed CAR-T company in AUS and US - YES.

Compared to investor and big pharma interest - NO.

All depends on data. The 2 NK-Cell trials have already delivered 1 complete response each but that isn't enough anymore. The GBM CAR-T has outperformed the Goldstandard but due to its high complexity applying it, it is not attractive atm.

All eyes on CDH17.

Negative, it is an Auto CAR-T, not allo, even if it can't be done the allo-way at this stage.
Positive: One of only a few CAR-Ts in development targeting solid cancers directly, especially gastric types.

Problem: Funding, as hardly anyone jumps on CAR-Ts atm unless it shows a paradigm shift

If the initial data suggest that CDH17 could be that treatment then yes, current MC is cheap. If it fails to impress like IMU's platforms atm, then no, way to expensive.

What is the likelihood of success? Hard to tell. Pre-Clinical data were impressive but so were those of CF33 and B-Cell too.

It is a big gamble, extremely high risk / reward.

GLTA